Benefit with anti-PD-L1

被引：0
|
作者：
Diana Romero
机构：
来源：
Nature Reviews Clinical Oncology | 2017年 / 14卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：71 / 71
相关论文
共 50 条
  • [1] IMMUNOTHERAPY Benefit with anti-PD-L1
    Romero, Diana
    NATURE REVIEWS CLINICAL ONCOLOGY, 2017, 14 (02) : 70 - 70
  • [2] Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1
    Jiming Chen
    Jie Yang
    Wenhui Wang
    Danfeng Guo
    Chengyan Zhang
    Shibo Wang
    Xinliang Lu
    Xiaofang Huang
    Pingli Wang
    Gensheng Zhang
    Jing Zhang
    Jianli Wang
    Zhijian Cai
    Cellular & Molecular Immunology, 2022, 19 : 1290 - 1301
  • [3] Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1
    Chen, Jiming
    Yang, Jie
    Wang, Wenhui
    Guo, Danfeng
    Zhang, Chengyan
    Wang, Shibo
    Lu, Xinliang
    Huang, Xiaofang
    Wang, Pingli
    Zhang, Gensheng
    Zhang, Jing
    Wang, Jianli
    Cai, Zhijian
    CELLULAR & MOLECULAR IMMUNOLOGY, 2022, 19 (11) : 1290 - 1301
  • [4] Hyperprogressive disease with anti-PD-1 and anti-PD-L1
    Brower, Vicki
    LANCET ONCOLOGY, 2016, 17 (12): : E527 - E527
  • [5] Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies
    Philips, George K.
    Atkins, Michael
    INTERNATIONAL IMMUNOLOGY, 2015, 27 (01) : 39 - 46
  • [6] Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma
    Simeone, Ester
    Grimaldi, Antonio M.
    Ascierto, Paolo A.
    MELANOMA MANAGEMENT, 2015, 2 (01) : 41 - 50
  • [7] Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
    Li, Xiao
    Eastham, Jeffrey
    Giltnane, Jennifer M.
    Zou, Wei
    Zijlstra, Andries
    Tabatsky, Evgeniy
    Banchereau, Romain
    Chang, Ching-Wei
    Nabet, Barzin Y.
    Patil, Namrata S.
    Molinero, Luciana
    Chui, Steve
    Harryman, Maureen
    Lau, Shari
    Rangell, Linda
    Waumans, Yannick
    Kockx, Mark
    Orlova, Darya
    Koeppen, Hartmut
    JOURNAL OF PATHOLOGY, 2024, 263 (02): : 190 - 202
  • [8] Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
    Naidoo, J.
    Page, D. B.
    Li, B. T.
    Connell, L. C.
    Schindler, K.
    Lacouture, M. E.
    Postow, M. A.
    Wolchok, J. D.
    ANNALS OF ONCOLOGY, 2015, 26 (12) : 2375 - 2391
  • [9] The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
    Tunger, Antje
    Sommer, Ulrich
    Wehner, Rebekka
    Kubasch, Anne Sophie
    Grimm, Marc-Oliver
    Bachmann, Michael Philipp
    Platzbecker, Uwe
    Bornhaeuser, Martin
    Baretton, Gustavo
    Schmitz, Marc
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (10)
  • [10] Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
    Puccini, Alberto
    Battaglin, Francesca
    Iaia, Maria Laura
    Lenz, Heinz-Josef
    Salem, Mohamed E.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
12345